Skip to main content

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low736.71
Day High761.96
Open:760.00
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Tipranks
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Edwards Lifesciences (EW)
Tipranks
Scotiabank Sticks to Their Hold Rating for Regeneron (REGN)
Tipranks
Truist Financial Sticks to Their Buy Rating for Regeneron (REGN)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Omnicell (OMCL)
Tipranks
Analysts’ Top Healthcare Picks: Merck & Company (MRK), Regeneron (REGN)
Tipranks
Analysts Conflicted on These Healthcare Names: Jade Biosciences (JBIO), Elevance Health (ELV) and Regeneron (REGN)
StockStory
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
REGN
GlobeNewswire
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
GlobeNewswire
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Zacks Investment Research
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Motley Fool
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
GlobeNewswire
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
GlobeNewswire
Regeneron Announces Investor Conference Presentations
StockStory
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky
REGN
Motley Fool
3 Catalysts That Could Send Teva Stock to $40 and Beyond
Tipranks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN)
Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
GlobeNewswire
Regeneron and Telix Announce Strategic Radiopharma Collaboration
GlobeNewswire
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Tipranks
Regeneron (REGN) Gets a Hold from Morgan Stanley
Tipranks
Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Regeneron (REGN)
StockStory
Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?
REGN
Zacks Investment Research
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
Newswire.ca
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
GlobeNewswire
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
StockStory
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
HIMS

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.